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Diabetes is a risk factor for dementia but relatively little is known about the epidemiology of 
the association.  A retrospective population study using Western Australian hospital inpatient, 
mental health outpatient  and death records was used to compare the age at index dementia 
record (proxy for onset age) and survival outcomes in dementia patients with and without pre-
existing diabetes (n=25,006; diabetes, 17.3%). Inpatient records from 1970 determined 
diabetes history in this study population with incident dementia between years 1990-2005.  
Dementia onset and death occurred an average 2.2 years and 2.6 years earlier, respectively, in 
diabetic compared to non-diabetic patients.  Age-specific mortality rates were increased in 
patients with diabetes.  In an adjusted proportional hazard model the rate of dying was 
increased with long duration diabetes, particularly with early age onset dementia.  In dementia 
diagnosed before age 65 years, those with a 15+ year history of diabetes died almost twice as 
fast as those without diabetes (Hazard Ratio 1.9, 95% Confidence Interval 1.3, 2.9).  These 
results suggest that in diabetes, dementia onset occurs on average 2 years early and survival 
outcomes are generally poorer.  The effect of diabetes on onset, survival and mortality is 
greatest when diabetes develops before middle age and after 15 years diabetes duration.  The 
impact of diabetes on dementia becomes progressively attenuated in older age groups.   
KEYWORDS Alzheimer disease, dementia, diabetes mellitus, epidemiology, mortality, 
proportional hazards models, retrospective studies, survival 
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Previous studies have demonstrated that diabetes is associated with an increased risk of 
dementia 
1-6
  and that the future global health burden from dementia is likely to be influenced 
by the worldwide increasing prevalence of diabetes 
7, 8
.  
Diabetes has consistently been associated with vascular dementia 
2, 9-15
 but reports on the 
association between diabetes and AD are less consistent. There are reports of a strong 
association between diabetes and risk of clinical AD 
2, 14, 16-18
, reports which find no 
association 
9, 11, 12, 15, 19
, and reports of subsets of people with diabetes who are at greater risk 
of developing AD
10, 20, 21
. Existing studies on the impact of diabetes on cognitive decline in 







 rates of cognitive decline in individuals with diabetes have been reported with 
AD and a more rapid rate of cognitive decline was reported with vascular dementia 
27
. The 
mechanisms that drive these associations are likely to be related to variable combinations of 
ischemic brain injury 
28, 29
 and AD-related neurodegeneration 
30
.In population models, 
relatively minor differences in incidence rates have been shown to have major impacts on 
future dementia projections 
31
 but there are few such studies in relation to diabetes and 
dementia.  A single study reported an early age of onset of vascular dementia in diabetes 
27
 
and shorter survival times have been reported with the combination of  AD and diabetes 
32
.  .    
The Western Australian Data Linkage System (WADLS) is an internationally renowned, 
population-based, validated, and ongoing data linkage system that creates links among a 
number of state health administrative data sets 
33-35
.  In the present study we used the Western 
Australian Data Linkage System   to identify all people with Alzheimer, vascular and non-
specific dementia documented in hospital and mental health outpatient records between 1990 
and 2005 with the aim of comparing age of dementia onset (using age at index dementia 
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record as a proxy),  age at death and length of survival with dementia in those with and 




 The Western Australian Data Linkage System  provided a de-identified extraction of linked 
data for years 1990 to 2005 from the Hospital Morbidity Data System (HMDS), Mental 
Health Information Services (MHIS) and Mortality Data System for all persons with a 
dementia diagnosis in any of these data sets.  The HMDS records all discharge summaries 
from all Western Australian acute hospitals (private and public) and day surgery clinics; the 
MHIS records all inpatient and outpatient contacts with public mental health services and all 
inpatient contacts with private mental health service providers.  Study data were obtained in 
December 2006 following approval from the Curtin University Human Research Ethics 
Committee and the Western Australian Department of Health Confidentiality of Health 
Information Committee. 
A case was defined as any person, aged 40 years or older, who had an index (first) record of 
dementia diagnosis in the HMDS or MHIS in the period 1 January 1990 to 31 December 
2005. The following International Classification of Disease-9-CM (ICD) and ICD-10-AM 
codes were used to identify cases. Alzheimer’s Dementia: 331.0, F00, G30; Vascular 
Dementia:  290.4, F01;   Non-Specific Dementia: 290.0, 290.1, 290.2, 290.3, 290.8, 290.9, 
294.1, 294.8, 331.2, F02.8, F03, F05.1, G31.1, G31.8, and G31.9.  Excluded from the study 
were (i) cases with any record of fronto-temporal, Creutzfeldt-Jakob, Huntington’s or 
Parkinson’s dementia, (ii) cases without at least one inpatient hospital admission in the five 
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year period prior to index record to reduce ascertainment bias related to hospitalization, (iii) 
cases with any record of dementia prior to 1990, and (iv) cases with first mention of diabetes 
recorded after their index dementia record.   A hierarchy was used to assign dementia type to 
cases with more than one dementia code in their health records; Alzheimer’s took precedence 
over vascular dementia which took precedence over the non-specific dementia diagnoses.  
Records from 1970 onwards were used to identify cases with diabetes mellitus using ICD-8 
code 250, ICD-9 codes 250.x, ICD-9-CM codes 250.x and  ICD-10-AM codes E10.x, E11.x, 
E13.x, E14.x for years 1970-1978, 1979-1987, 1988-1999, 2000-2005 respectively.  No ICD-
8 codes were available to distinguish between different types of diabetes mellitus. Therefore, 
the above ICD-9, ICD-9-CM and ICD-10-AM codes included type1, type 2, other specified 
and unspecified diabetes mellitus. As the exact date of diabetes onset was not known, the 
duration of diabetes was defined as the number of years between the date of the index 
diabetes hospital record and the date of the index dementia record.   Diabetes duration was 
then categorized as less than 6 years, 6-10 years, 11-15 years and greater than 15 years 
duration.  
Linked health records were also used to determine pre-existing comorbidity using the 
Charlson Comorbidity Index 
36
. The comorbidity index consisted of groups of ICD codes 
weighted according to mortality risk (excluding dementia and diabetes); the total weighted 
index was divided into three discrete intervals. Any mention of each of the diagnostic 
categories on any hospital admission with a separation date within five years of index 
dementia record contributed to the comorbidity index 
37
.  Comorbidities due to myocardial 
infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, 
chronic pulmonary disease, rheumatic disease, peptic ulcer disease, hemi- or paraplegia, renal 
disease, tumors, lymphoma, leukemia, liver disease and metastatic solid tumor were included 




Data and statistical analysis 
Multivariate linear regression models were used to investigate factors associated with age at 
onset of dementia and age at death with dementia; the factors included diabetes duration, sex, 
dementia type, number of hospitalizations in the five year period prior to index dementia 
record, the source of the index record, comorbidity at year of index record and year of index 
record.  Sex and dementia type were included as they are known to be related to age of 
dementia onset.  Numbers of hospitalizations were included because cases with more frequent 
hospital admissions prior to the index record were expected to appear younger at time of 
index dementia because of increased surveillance and recording of their health status.  The 
source of index-record type was considered a potential confounder e.g. mental health 
outpatient services are less likely to be provided to people from residential aged-care 
facilities.  Year of index record was included to adjust for possible changes in hospital 
admission patterns over the 15 years of the study and changes in treatment and preventive 
practices.  Box-Cox power transformations of the age variables were used to correct for the 
skewness of the residuals and the appropriate back transformation of model beta coefficients 
were performed.  The effect of diabetes duration on both age at index record and age at death 
was found to be modified by the type of dementia.  
Survival analysis was used to estimate differences in mortality by diabetes duration. Due to 
both the relatively low level of censoring (27.7%) which can increase bias if using time-on-
study as the time scale and the presence of covariates strongly associated with age, age was 
used as the time scale with left truncation at age of index record 
38
. This allows control for the 
strong association of age with death and interpretation of the hazard rate as an age-specific 
mortality rate.  Study censor date was 31 December 2005 or date of last inpatient or outpatient 
8 
 
visit if prior to censor date. Patients who died during the index record admission or within 30 
days of separation were excluded from the survival analysis. The average un-adjusted age-
specific mortality rates for the cohort were obtained from the weighted kernel smooth of the 
estimated hazard function. The relative rates of death by diabetes duration were estimated 
from covariate adjusted regression using flexible parametric proportional hazards models 
constructed with restricted cubic splines 
39
 . Multivariate model building started with 
inclusion of all significant univariate predictors, age group at index dementia record, diabetes 
duration, type of dementia, sex, comorbidity and source of index record.  The observed non-
proportional hazards for comorbidity and source of index record were accounted for by 
including them in the final model as time-varying covariates with one degree of freedom. All 
two-factor interactions with diabetes duration, the primary risk factor of interest, were 
examined. Median survival time since time index record for each age group by diabetes 
duration was estimated by setting time since index record as analysis time.  Data manipulation 
was performed using SAS and statistical analysis using Stata 11 (College Station, Texas). 
RESULTS 
Cohort characteristics and age at dementia onset 
There were 32,768 patients with an index record of dementia between 1990 and 2005 (mean 
(SD), age 81.5 (8.3) years, 38.8% male, 13.9% with diabetes).  After excluding 6,663 
dementia cases without a prior hospital admission in the five year period prior to index 
records (age 81.1 (8.4) years, 33.7% male, 3.8% with diabetes) and 1,099 cases where 
diabetes was first recorded after date of index dementia (age 79.7 (8.6) years, 39.2% male) 
there remained a study cohort of 25,006 dementia cases (age 81.7 (8.2) years, 40.2% male, 
17.3% with diabetes).  Only 298 cases had Type 1 Diabetes (age 76.9 (8.9) years, 49.0% 
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male.   The study cohort included 848 people (3.5%) aged 40-64years, 3168 (12.7%) aged 65-
74 years, 11049 (44.2%) aged 75-84 years and 9944 (39.8%) aged 85+ years.   
Of the cohort, 23,811(95.2%) and 5539 (22.2%) cases had at least one dementia diagnosis 
documented in inpatient hospital  (including general and psychiatric hospitals) and mental 
health outpatient records respectively, with 4344 (17.4%) having a dementia diagnosis in both 
inpatient and outpatient records. The index dementia record was located in the outpatient and 
inpatient records  in 3276 (13.1%) and 21,739 (86.9%) cases respectively.  A total of 
1195(4.8%) cases had no dementia documented in inpatient hospital records.  For the 2072 
(8.2%) cases with their index record in the mental health outpatient records and a subsequent 
diagnosis in the inpatient hospital records, the mental health outpatient record ascertained the 
dementia diagnoses a median of 18 weeks earlier (Interquartile range 3 – 69).  Of the 18,086 
cases that died, dementia was also documented in 7933(43.9%) death records and 9187 
(50.8%) had dementia documented in at least two data sets. 
Diabetes was more commonly recorded in the younger age groups of the dementia cohort 
with 23.2% of 40-64 year olds, 24.1% of 65-74 year olds, 18.6% of 75-84 year olds and 
13.1% of those 85+ years having diabetes (Cochran-Armitage trend test P < 0.0001). Diabetes 
was associated with an increased proportion of males, vascular dementia, comorbidity, more 
frequent hospitalizations (all χ
2
 p-values P < 0.001) and being sourced from inpatient records 
(P=0.004) when compared with non-diabetes. Overall, cases with diabetes were an average 
2.2 (95% Confidence Interval (CI) 2.0, 2.5, t-test P < 0.001) years younger at the time of 
index dementia record and this trend of younger index age for diabetes was consistent when 
stratified by sex, dementia type, comorbidity, record source and number of hospitalizations 
(Table 1).  In a multivariate regression model of age at index record (age at dementia onset), 
diabetes remained a significant independent predictor of younger age at dementia onset after 
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adjusting for all other variables (Table 2). There were differences in mean age at dementia 
onset by duration of diabetes and by dementia type.  These differences were most marked 
with vascular dementia; for example, where diabetes had been present for 15 years or more, 
the age at index record was 5.7 years earlier than non-diabetic cases.  The pattern with AD 
and non-specific dementia was similar but with less marked age difference (2.4 and 3.4 years 
respectively for longest duration diabetes). 
Mortality and survival with dementia 
By December 2005, 72.3% (18,083 cases) of the cohort had died. Of those who had died, the 
diabetic patients had dementia first recorded 2.3 (95% CI 1.9, 2.6) years younger than those 
without diabetes (mean (SD), age 80.6 (8.1) vs 82.8 (7.6) years, P < 0.0001) and the age at 
death occurred an average 2.6 (95% CI 2.3, 2.9) years younger (82.4 (8.0) vs 85.0 (7.4) years, 
P < 0.0001).  A general trend of younger mean age at death was observed with increasing 
diabetes duration (Table 2) and this was quantified as dying on average 0.20 (95% CI 0.17, 
0.22) years younger with each increasing year of diabetes duration in an adjusted linear 
regression model with duration of diabetes included as a continuous variable in years.  
After excluding 2909 dementia cases  who died during the index dementia hospital admission 
or within 30 days of index record, there remained 22,097 cases with follow-up time for 
survival analysis. Survival analysis was used to estimate age-specific mortality rates for the 
cohort by a history of diabetes (Figure 1).  The mortality rate in dementia patients with 
diabetes was higher than those without diabetes and this effect was stronger at a younger age.   
The association of mortality and diabetes remained after adjustment for covariates in a 
multivariate flexible parametric proportional hazards model and was found to be modified by 
age at index record and duration of diabetes (Figure 2).   There was a significant trend of 
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duration of diabetes on rate of death in all age groups except those who had dementia 
diagnosed when aged over 85 years. The effect was most marked in those diagnosed with 
dementia at a young age.  When dementia was diagnosed before age 65 years, those with 
longest duration diabetes (more than 15 years) died at almost twice the rate as those without 
diabetes (Hazard Ratio (HR) 1.9, 95%CI 1.3, 2.9).  The death rates were also significantly 
greater with long duration diabetes with the 65-74 year and 75-84 year age groups although 
the effect was less marked (HR 1.5,  (95%CI 1.1, 1.9) and 1.4 (95%CI 1.2, 1.6), respectively).  
Median survival times from date of index record for these age groups by length of diabetes 
duration are shown in Table 3 with longer duration of diabetes having a bigger impact on 




In the present study we used administrative health datasets to explore the impact of pre-
existing diabetes on a surrogate measure of age at dementia onset and subsequent survival in 
the Western Australian population.   Over 17% of dementia cases had pre-existing diabetes 
but the prevalence was substantially greater, affecting almost 1 in 4 cases, in those with early-
onset dementia (<65 years).   Dementia in those with pre-existing diabetes developed an 
average 2.2 years earlier than in non-diabetic cases and was associated with an increased 
mortality rate and a shorter survival time after dementia onset.   The magnitude of diabetes-
related differences in survival and mortality rate after onset were relatively modest overall.  
We conclude that at the population level, the increased risk of dementia due to diabetes is 
explained predominantly by an early age of onset rather than by a major change in the natural 




To our knowledge this is the first epidemiological study to include every identified dementia 
case from a large population database.  Most previous large population studies have studied 
elderly populations only, hence missed any impact of diabetes on early-onset dementia 
1
. The 
few studies that assessed mid-life diabetes then late-life dementia did not examine mortality 
rates and survival
2, 3
. The public health significance of a 2.2 year age difference seems 
modest, yet it has been estimated that an intervention able to delay the onset of AD by 2 years 
would reduce the projected quadrupling of AD prevalence by 2050 by over 20% 
40
.  Diabetes 
was previously estimated to account for 7-13% of the population attributable risk for incident 
dementia 
41
 but this was largely based on studies of older populations.  Given that the 
incidence and prevalence of type 2 diabetes  are increasing worldwide because of population 
ageing and the global obesity problem 
7, 8, 42
, the impact of diabetes on dementia projections 
based on the present study is likely to be substantially greater than previously considered. 
The population-based nature of this study meant that the diagnosis of dementia sub-types 
were documented by a range of medical staff of varying seniority and from various health 
care settings and specialties. Whilst their diagnostic validity cannot be determined, we did 
find differences by dementia sub-types consistent with the known literature 
43
. The effect was 
most marked in those who were diagnosed with vascular dementia which developed three 
years earlier whilst AD developed a little over one year earlier in those with diabetes.  The 
duration of diabetes was an important modifier of the relationship between diabetes and 
dementia onset and survival, with the greatest impact on younger cases with long diabetes 
duration.  Again this was most marked with vascular dementia, a condition known to occur 
with an earlier age of onset in diabetes 
44
 but was also seen with AD and non-specific 
dementia.  Both microvascular complications and worsening macrovascular burden are 
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strongly associated with long diabetes duration 
45
 suggesting that diabetes contributes in the 
pathophysiology and clinical expression of dementia by cerebral microvascular and/or 
macrovascular mechanisms.  Vascular lesions may also augment the cerebral burden of AD-
related pathological changes and accelerate the clinical expression of AD 
46
.  Alternatively, it 
has been suggested that several of the metabolic abnormalities in type 2 diabetes, including 
insulin resistance, hyperglycaemia and chronic inflammation, promote AD-related changes 
including beta-amyloid accumulation 
47, 48
.  Type 2 diabetes is a chronic progressive condition 
where escalating medical therapies including exogenous insulin and/or insulin secretogogues 
are required to control the worsening metabolic deficits 
49
. Cerebral beta-amyloid deposition 
is a gradual slow process that takes a decade or more to develop, in which case years of 
diabetes may be required to alter this pathway substantially.   
The impact of diabetes duration on mortality was attenuated in older age and was absent in 
those aged ≥ 85 years.  This may reflect a survivor effect, i.e. only some people are able to 
survive the ravages of long duration diabetes and live long enough to develop late-onset 
dementia.  Extrapolating backwards from figure 2, the excess risk of death with dementia due 
to diabetes is mainly confined to those diagnosed with diabetes before age 65 years who 
subsequently survive with diabetes for around 15 years.  Whilst the present study cannot 
definitively distinguish whether increased mortality rates reflect faster rates of cognitive 
decline or is due to other diabetes-related comorbidity, the differences persisted after 
statistical adjustment for hospital admissions and comorbidities.   
The strengths of our study include the large population-based sample size, the use of the 
Western Australian Data Linkage System that has been demonstrated to provide accurate 
hospital, mental health clinic and death data within known limitations for case ascertainment 
and the ability to control for a range of important modifiers and confounders including 
14 
 
estimated duration of pre-morbid diabetes.  The main limitations of the study are the use of 
health administrative datasets to obtain proxy measures of diabetes and dementia onset  and 
the reliance on routine clinical diagnoses for diabetes and dementia sub-types. While all cases 
in this study required a physician diagnosis of dementia, the specific diagnostic criteria used 
by each physician for dementia and all other medical conditions are not known and the 
dementia diagnoses could not be verified.  However in a Danish study, 86% of dementia 
diagnoses and 81% of AD diagnoses in hospital registers were correct 
50
.  An Australian audit 
reported that the sensitivity, positive predictive value and kappa value for dementia diagnoses 
were 67%, 76% and 0.71, respectively, suggesting substantial agreement between medical 
charts and registry data
51
. . By including records from psychiatric outpatient contacts in 
addition to hospital inpatient records we improved dementia case ascertainment by 5% and 
provided earlier estimates for dementia onset in a further 8% of cases. .  The greater 
likelihood of diabetes patients being hospitalized may have led to both increased and earlier 
detection of dementia cases with diabetes in the registers.  To minimize this problem we 
included only dementia cases who had at least one hospital admission in the five-year period 
before index date and adjusted for number of hospitalizations within this period.  As expected, 
cases with diabetes had more frequent hospital admissions, although the survival and age at 
onset differences persisted after adjustment for number of hospitalizations. The lower 
prevalence of diabetes among the excluded cases suggests that we excluded the more 
“healthy” dementia cases, so the differences between diabetic and non-diabetic cases 
observed in this study may be an underestimate of the true population estimate.  Under-
diagnosis of diabetes can also occur during hospitalization and misclassification here would 
be expected to dilute the effects that we found.  We were also unable to control for a range of 
potential confounders including low educational status, which is associated with both diabetes 
52, 53
 and dementia 
54
 and could therefore contribute to our findings. There could also have 
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been differences in degree of cognitive impairment at the time of index dementia record that 
could have skewed the results. While we were also unable to adjust for other potentially 
important variables, such as diet, exercise and glycemic control, we were able to adjust for 
diseases associated with these risk factors, incorporated into the Charlson Comorbidity Score. 
In summary, diabetes was associated with an earlier age of onset of dementia and an earlier 
age of death through a reduced survival time compared with patients with dementia without 
diabetes.  The increased risk of dementia due to diabetes that is seen in population studies is 
explained by an average 2-year earlier age at onset of disease rather than because of a 
prolonged disease course.  These findings, amplified in early-onset dementia and by long 
duration diabetes, have major implications for estimating the future dementia disease burden 
due to diabetes as well as clinical implications for affected patients and their families.  
16 
 
Table 1:  Characteristics of 25,006 Western Australian Dementia Patients by Diabetes Status 
at Time of Index Dementia Record (1990-2005).  
 No Diabetes Diabetes Age Difference (Years) 
 No. % Age(SD) 
Years 




95% CI  
Sex         
Male 8,169 39.5 80.3 (8.4) 1,887 43.7 78.5 (8.4) 1.8 1.4-2.3 
Female 12,521 60.5 83.3 (7.7) 2,429 56.3 81.0 (8.0) 2.3 1.9-2.6 
Dementia Type         
Alzheimer 8,888 43.0 81.8 (7.4) 1,471 34.0 80.6 (7.4) 1.2 0.7-1.6 
Non-specific 9,794 47.3 83.0 (8.5) 2,238 51.9 80.4 (8.5) 2.6 2.2-3.0 
Vascular   2,008 9.7 79.4 (8.5) 607 14.1 76.5 (8.5) 2.9 2.2-3.7 
Comorbidity
 
         
0 8974 43.4 81.5 (8.6) 1,274 29.5 79.6 (8.4) 1.9 1.4-2.4 
1-2 7356 35.6 82.7 (7.8) 1,617 37.5 80.4 (8.2) 2.2 1.8-2.7 
3-18   4,360 21.1 82.4 (7.6) 1,425 33.0 79.5 (8.2) 2.9 2.4-3.3 
Index Record
b
         
Outpatient 2,756 13.3 78.9 (9.2) 511 11.8 77.3 (8.9) 1.7 0.8-2.5 
Inpatient 17,934 83.0 82.6 (7.8) 3,805 88.2 80.2 (8.0) 2.3 2.1-2.6 
Hospitalizations         
1-2 8,391 40.6 82.0 (8.1) 1,143 26.5 80.5 (7.8) 1.6 1.1-2.1 
3-4 5,152 24.9 82.5 (8.1) 1,002 23.3 80.6 (7.8) 1.9 1.3-2.4 
5+ 7,147 34.5 81.9 (8.2) 2,171 50.3 79.3 (8.7) 2.7 2.3-3.1 
Total    20,690 100.0 82.1 (8.1) 4,316 100.0 79.9 (8.3) 2.2  1.9-2.5 
 
SD, standard deviation. CI, confidence interval.  
 a
Comorbidity, Charlson’s weighted 
comorbidity index score.  
b
Outpatient, public mental health outpatient clinics; Inpatient, 
private and public hospitals. 
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Table 2:  Multivariate Linear Model Estimating Mean Differences in Age at Time of Index 
Dementia Record (n= 25006) and Age at Death (n=18083) by Clinical and Demographic 
Variables, Western Australia, 1990-2005. 
  Age at Index Dementia Record
a
  Age at Death
a
 
Variable ∆ mean   95% CI P-value ∆ mean  95% CI P-value 
Alzheimer’s Disease       
No diabetes history 0 (referent)   0   
Diabetes 0-5 years -1.1 -1.6, -0.6 <0.001 -0.8  -1.4, -0.2  0.006 
Diabetes 6-10 years -1.2  -2.0, -0.4  0.006 -1.1 -2.1, -0.2  0.022 
Diabetes 11-15 years -1.4  -2.5, -0.3  0.014 -2.1 -3.3, -0.9  0.001 
Diabetes > 15 years -2.4  -3.7, -1.1 <0.001 -3.8 -5.2, -2.3 <0.001 
Vascular Dementia       
No diabetes history 0   0   
Diabetes 0-5 years -2.6  -3.6, -1.7 <0.001 -2.5 -3.5, -1.4 <0.001 
Diabetes 6-10 years -2.3  -3.7, -1.0 <0.001 -2.1 -3.6, -0.7   0.004 
Diabetes 11-15 years -3.3  -5.2, -1.4 <0.001 -2.8 -4.9, -0.7   0.010 
Diabetes > 15 years -5.7 -8.1, -3.4 <0.001 -6.9 -9.5, -4.4 <0.001 
Non-specific Dementia      
No diabetes history 0   0   
Diabetes 0-5 years -2.7 -3.1,-2.2 <0.001 -2.6 -3.1, -2.1 <0.001 
Diabetes 6-10 years -2.2 -2.0, -0.3 <0.001 -2.4 -3.2, -1.7 <0.001 
Diabetes 11-15 years -2.8 -3.7, -1.9 <0.001 -3.1 -4.1, -2.0 <0.001 
Diabetes > 15 years -3.4 -4.4, -2.4 <0.001 -3.8 -4.9, -2.6 <0.001 
Sex       
                                 Male 0   0   
Female 2.6 2.4, 2.8 <0.001 3.1 2.9, 3.3 <0.001 
Index Record       
Inpatient 0   0   
Outpatient -2.8 -3.1, -2.5 <0.001 -1.6 -1.9, -1.3 <0.001 
Index Year       
1990-94 0   0   
1995-99 0.5 0.2, 0.7 <0.001 0.6  0.4, 0.9 <0.001 
2000-05 1.5 1.2, 1.7 <0.001 1.1 0.8, 1.3 <0.001 
Comorbidity       
18 
 
  Age at Index Dementia Record
a
  Age at Death
a
 
0 0   0   
1-2 1.3 1.1, 1.5 <0.001 0.4 0.2, 0.7  0.001 
3-18 1.3 1.1, 1.6 <0.001 -0.2 -0.5, -0.1  0.1 
Hospitalizations -0.4 -0.4, -0.3 <0.001 -0.4 -0.5, -0.3 <0.001 
Abbreviations:  ∆ mean, mean difference; CI, confidence interval; Comorbidity , Charlson’s 




 Regression model adjusted for diabetes duration, sex, dementia type, number of 
hospitalizations in the five year period prior to index dementia record, the source of the index 
record, comorbidity at year of index record and year of index record.  Duration of diabetes 
and dementia type was entered in the model as an interaction term.  
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 Percentile Survival Time From Time of Index Dementia 
Record by Age Group and Diabetes history (n=22,097), Western Australia, 1990-2005. 
Age at Index Dementia Record Diabetes Duration N Survival Time (years) 
  
25% Median (50%) 75% 
40-64 years No diabetes 603 2.5 5.7 11.5 
 
0-5 years 94 1.4 3.7 7.7 
 
6-10 years 35 1.9 3.6 10.2 
 
11-15 years 27 1.3 2.8 5.9 
 
>15 years 31 0.5 2.7 5.7 
65-74 years No diabetes 2219 1.6 3.5 6.4 
 
0-5 years 380 1.0 3.3 6.6 
 
6-10 years 152 1.0 2.7 5.7 
 
11-15 years 75 1.0 2.5 6.7 
 
>15 years 71 0.9 2.0 4.4 
75-84 years No diabetes 8025 1.0 2.5 4.8 
 
0-5 years 994 0.7 2.2 4.4 
 
6-10 years 428 0.6 1.9 4.5 
 
11-15 years 215 0.6 2.0 4.0 
 
>15 years 176 0.6 1.2 3.6 
85+ years 
No diabetes 7473 0.7 1.8 3.4 
0-5 years 602 0.6 1.6 3.1 
6-10 years 258 0.6 1.6 3.1 
11-15 years 149 0.5 1.4 2.9 
>15 years 90 0.6 1.3 2.9 
      All cases a 
 
22097 0.8 2.3 4.4 
a 
Cases that died at time of index record or within 30 days of separation from index record 





Figure 1 Legend: Age-specific mortality rate of the dementia cohort for those with a history 
of diabetes before index dementia record (grey line) and those without a history of diabetes 
(black line).  pys, person years.  95% confidence intervals are indicated by shading.  
Dementia cohort includes 22097 Western Australians with index dementia records between 




Figure 2 Legend:  Relative rate of death (hazard ratio) for dementia cases with an increasing 
history of diabetes duration from 0-5 years (darkest square), 6-10 years (dark square), 11-15 
years (pale square) and more than 15 years (palest square) compared to dementia cases with 
no history of diabetes (●) and similar age at index dementia record estimated from a 
proportional hazards model.  Model was also adjusted for type of dementia, comorbidity, sex 
and source of record.  95% confidence intervals indicated by error bars and p-value for trend 
test of increasing history of diabetes duration. (n=22,097 Western Australians with index 
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